Journal of the advanced practitioner in oncology最新文献_第4页

Evaluating the Impact of a Clinical Pharmacist in Patients Receiving New Chemotherapy for Breast Cancer: Analysis of a Pilot Study. 评估临床药师对接受新化疗的乳腺癌患者的影响：一项初步研究的分析。

Journal of the advanced practitioner in oncology Pub Date : 2024-11-04 DOI: 10.6004/jadpro.2024.15.8.19

Carissa Joelle Ganihong, Anshika Singh, Roseanne Dimarco

{"title":"Evaluating the Impact of a Clinical Pharmacist in Patients Receiving New Chemotherapy for Breast Cancer: Analysis of a Pilot Study.","authors":"Carissa Joelle Ganihong, Anshika Singh, Roseanne Dimarco","doi":"10.6004/jadpro.2024.15.8.19","DOIUrl":"10.6004/jadpro.2024.15.8.19","url":null,"abstract":"Purpose: Breast cancer treatment may include chemotherapy, which is associated with significant toxicities. At the Sidney Kimmel Cancer Center at Jefferson Health, a pilot program was developed to add an oncology clinical pharmacist to the breast cancer clinic. The purpose of this study is to identify the impact of the clinical pharmacist in supportive care management, add to existing literature discussing the impact of the clinical pharmacist in ambulatory oncology settings, and justify future, permanent ambulatory oncology pharmacist positions within the institution.Methods: This single-center retrospective chart review assesses interventions made by the clinical pharmacist in patients with any stage of breast cancer who presented to the breast clinic for new chemotherapy treatment between September 1, 2020, and February 28, 2021. The primary outcome was to describe clinical pharmacist interventions at the first follow-up encounter after chemotherapy initiation. Secondary outcomes included classifying and quantifying total interventions and comparing intervention details between total and included patients within the 6-month timeframe.Results: Of 44 included patients, 29 had a follow-up encounter. The clinical pharmacist directly managed 33% of the 58 patient-reported adverse drug effects. In 6 months, the clinical pharmacist made 1,068 interventions spanning 189.6 documented hours. The most common interventions were coordination of care, education, and supportive care pharmacotherapy interventions.Conclusion: This study identified the pharmacist's role in supportive care management and reports the successful integration of a clinical pharmacist into a breast cancer clinic. Future directions include conducting prospective studies to further explore the impact of the clinical pharmacist on treatment outcomes.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medullary Renal Cell Carcinoma: A Case Study. 肾髓样细胞癌一例研究。

Journal of the advanced practitioner in oncology Pub Date : 2024-11-01 DOI: 10.6004/jadpro.2024.15.7.4

Kate Townsend

引用次数: 0

Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors. Obinutuzumab输注相关反应：发生率、严重性和危险因素的多中心回顾性评估

Journal of the advanced practitioner in oncology Pub Date : 2024-11-01 DOI: 10.6004/jadpro.2024.15.7.2

Erin Hickey Zacholski, Sarah Rugh, Jenna Marshall, Pramit Nadpara, Donald Moore

{"title":"Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors.","authors":"Erin Hickey Zacholski, Sarah Rugh, Jenna Marshall, Pramit Nadpara, Donald Moore","doi":"10.6004/jadpro.2024.15.7.2","DOIUrl":"10.6004/jadpro.2024.15.7.2","url":null,"abstract":"Introduction: Despite standard prevention strategies, obinutuzumab carries a significant risk of infusion-related reactions (IRRs) for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Reported rates of IRRs vary in phase III clinical trials evaluating obinutuzumab-containing regimens. Although obinutuzumab has a higher rate of severe (grade 3 and higher) IRRs than rituximab, clinical risk factors predicting IRR have not been identified, and therefore strata informing patient-specific risk of IRR have not been applied in practice.Methods: This multicenter, retrospective evaluation of patients with CLL/SLL estimated the incidence of obinutuzumab-related IRRs and evaluated risk factors for the development of IRR in a real-world population.Results: 68 patients with untreated or previously treated CLL/SLL were included in the analysis, with the majority being older adult (median age = 70) males (61.8%) with Rai stage III and IV CLL. All-grade IRRs occurred in 25% of patients, and severe IRRs occurred in 1.5% of patients. Of the variables evaluated, absolute lymphocyte count was a significant predictor (p ≤ .05) of the odds of experiencing an IRR in patients receiving obinutuzumab.Conclusion: Obinutuzumab IRR rates in a real-world population were comparable to most phase III clinical trial results succeeding implementation of split dosing and standard premedication. Absolute lymphocyte count is a statistically significant predictor for increased odds of experiencing an IRR. Future research evaluating risk-adapted obinutuzumab administration strategies is needed to recommend a specific approach.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 7","pages":"437-443"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143018976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancreatic Cancer: The Advanced Practitioner's Role in Early Diagnosis and Management. 胰腺癌：高级医生在早期诊断和治疗中的作用。

Journal of the advanced practitioner in oncology Pub Date : 2024-11-01 DOI: 10.6004/jadpro.2024.15.7.3

Lindsay Knox

引用次数: 0

Immediate Patient Access to Test Results and the Impact on Advanced Practitioners. 患者立即获得测试结果和对高级从业人员的影响。

Journal of the advanced practitioner in oncology Pub Date : 2024-11-01 DOI: 10.6004/jadpro.2024.15.7.1

Beth Faiman

引用次数: 0

Optimizing Treatment of BRAFV600E-Mutant Metastatic NSCLC With Encorafenib and Binimetinib: A Practical Resource for Advanced Practice Providers. 优化brafv600e突变体转移性NSCLC的恩科非尼和比尼美替尼治疗：高级实践提供者的实用资源

Journal of the advanced practitioner in oncology Pub Date : 2024-09-12 DOI: 10.6004/jadpro.2024.15.8.16

Kelly Goodwin, Kristi Orbaugh, Kirsten Duncan, Erica Stumpf

{"title":"Optimizing Treatment of BRAFV600E-Mutant Metastatic NSCLC With Encorafenib and Binimetinib: A Practical Resource for Advanced Practice Providers.","authors":"Kelly Goodwin, Kristi Orbaugh, Kirsten Duncan, Erica Stumpf","doi":"10.6004/jadpro.2024.15.8.16","DOIUrl":"10.6004/jadpro.2024.15.8.16","url":null,"abstract":"The BRAF V600E mutation aberrantly activates the mitogen-activated protein kinase (MAPK) pathway, subsequently resulting in uncontrolled cellular proliferation, survival, and dedifferentiation. Approximately 2% of patients with non-small cell lung cancer (NSCLC) have a BRAF V600E mutation. BRAF and MEK inhibitor combination therapy targets two kinases within the MAPK pathway. Encorafenib (Braftovi) and binimetinib (Mektovi) are potent oral inhibitors of BRAF and MEK, respectively. With the recent US Food and Drug Administration approval of encorafenib plus binimetinib, adult patients with BRAF V600E-mutated metastatic NSCLC have an additional treatment option. In the phase II PHAROS study, encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee and exhibited a manageable safety profile in this patient population. This article provides an overview of the efficacy and safety of encorafenib plus binimetinib and uses a fictional patient case to illustrate the role of advanced practice providers in providing individualized patient care and identifying and managing adverse reactions.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-17"},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination. 双特异性治疗的无缝导航：优化管理和门诊访问重点协调。

Journal of the advanced practitioner in oncology Pub Date : 2024-09-11 DOI: 10.6004/jadpro.2024.15.8.15

Zahra Mahmoudjafari, Amir Ali, James Davis, Tyler Sandahl, Victoria Nachar, Robert Mancini

{"title":"Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination.","authors":"Zahra Mahmoudjafari, Amir Ali, James Davis, Tyler Sandahl, Victoria Nachar, Robert Mancini","doi":"10.6004/jadpro.2024.15.8.15","DOIUrl":"10.6004/jadpro.2024.15.8.15","url":null,"abstract":"Bispecific antibodies (BsAbs) have emerged as crucial therapeutic agents for patients with relapsed/refractory diffuse large B-cell lymphoma, multiple myeloma, and most recently, lung cancer. These therapies have demonstrated remarkable efficacy in clinical trials; however, multidisciplinary collaboration is essential to ensure optimal patient outcomes amid the operational complexities associated with BsAb therapy. As BsAbs are being prepared for broader adoption, clinicians and treatment centers must navigate operational challenges, including financial considerations, patient selection, caregiver involvement, and transitions of care. Centers must also be knowledgeable to manage toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. We therefore convened a panel of academic and community practice pharmacists with experience using BsAbs in clinical trial and standard-of-care settings to provide comprehensive recommendations with a focus on successful onboarding and operationalization of BsAb therapies.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-16"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Do Patients With Cancer Know, or Want to Know, About Genomic Tumor Sequencing and Genetic Testing? A State-of-the-Art Review. 关于肿瘤基因组测序和基因检测，癌症患者知道或想知道什么？最新的评论。

Journal of the advanced practitioner in oncology Pub Date : 2024-09-11 DOI: 10.6004/jadpro.2024.15.8.14

Lisa Stewart, Linda D Ward

{"title":"What Do Patients With Cancer Know, or Want to Know, About Genomic Tumor Sequencing and Genetic Testing? A State-of-the-Art Review.","authors":"Lisa Stewart, Linda D Ward","doi":"10.6004/jadpro.2024.15.8.14","DOIUrl":"10.6004/jadpro.2024.15.8.14","url":null,"abstract":"Molecular profiling (MP), which involves testing tissue, blood, or other body fluids to identify biomarkers, has become increasingly important in cancer treatment. Genomic tumor sequencing, a specific type of MP, is commonly used to identify specific gene variants or proteins that can be targeted for treatment. Germline testing is also routinely recommended for certain cancers. Low levels of genomic literacy among cancer patients, coupled with increasingly complex test results, challenge clinicians to communicate results and provide appropriate education. In addition, patients may have varying preferences for the level of information they desire and are able to process. This state-of-the-art review explores cancer patients' expectations, attitudes, knowledge, satisfaction, and concerns as they undergo molecular profiling. A search was conducted through four databases to identify studies from 2016 to 2022 to explore cancer patients' knowledge and preferences regarding genomic testing. Nineteen studies met the inclusion criteria. Most studies revealed that people with cancer have low levels of knowledge regarding MP, albeit with significant variability. Patients primarily desired MP to identify new treatment options and increase survival. While patients relied on their providers to interpret test results, they wanted to be informed of all results, mainly if those results might guide treatment decisions or future care planning. Most patients, especially those with low genomic/genetic knowledge, tended to overestimate the personal benefits of MP. Further study is needed to provide tailored education to fulfill patients' information needs.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementing a Validated Multi-Symptom Assessment Tool During Telephone Triage to Reduce Oncology Patient Emergency Room Visits. 在电话分诊中实施有效的多症状评估工具以减少肿瘤患者急诊室就诊。

Journal of the advanced practitioner in oncology Pub Date : 2024-09-11 DOI: 10.6004/jadpro.2024.15.8.12

Kristin Neves

{"title":"Implementing a Validated Multi-Symptom Assessment Tool During Telephone Triage to Reduce Oncology Patient Emergency Room Visits.","authors":"Kristin Neves","doi":"10.6004/jadpro.2024.15.8.12","DOIUrl":"10.6004/jadpro.2024.15.8.12","url":null,"abstract":"Cancer treatments induce multiple unwanted side effects that often go unrelieved, resulting in emergency room (ER) visits. Oncology clinics have established triage clinics (TCs) for symptom management, thereby improving access to care and decreasing ER utilization. In addition, evidence proves that validated patient-reported outcome (PRO) tools support improved symptom management and decreased ER visits. This quality improvement project aimed to determine if or to what degree implementing the MD Anderson Symptom Inventory (MDASI) tool decreases emergency room visits, with or without hospitalizations, in a South Florida outpatient oncology clinic. The MDASI tool was implemented in a TC during symptom management telephone triage. A statistically significant difference was observed in community ER visits and hospitalizations using a significance level of p < .05. The pre-implementation (n = 14, 29.8%) and post-implementation (n = 10, 23%) values (χ2 [N = 47] = 12.66, p = .008) confirmed a reduction in ER visits by 6.8 percentage points. In addition, pre-implementation (n = 8, 17%) and post-implementation (n = 10, 21%) values (χ2 [N = 47] = 25.69, p = .006) confirmed a mean increase of two more hospitalizations (4%) in patients after MDASI implementation, likely reflecting an improved patient understanding of appropriate ER utilization. The MDASI tool supported early symptom assessment and management while identifying patient knowledge gaps. This project confirms that PRO tools allow patients to assign meaning to their symptoms, improve communication, and reduce unnecessary ER visits.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding the Toolbox: A Palliative Care Lecture Series for Oncology Advanced Practice Providers. 扩展工具箱：肿瘤学高级实践提供者的姑息治疗系列讲座。

Journal of the advanced practitioner in oncology Pub Date : 2024-09-11 DOI: 10.6004/jadpro.2024.15.8.13

Heidi Mason, April Bigelow, Christina Conrad, Karen Harden, Deborah Price, Diane Bohn, Natasha Mason

{"title":"Expanding the Toolbox: A Palliative Care Lecture Series for Oncology Advanced Practice Providers.","authors":"Heidi Mason, April Bigelow, Christina Conrad, Karen Harden, Deborah Price, Diane Bohn, Natasha Mason","doi":"10.6004/jadpro.2024.15.8.13","DOIUrl":"10.6004/jadpro.2024.15.8.13","url":null,"abstract":"Purpose: Initiation of early palliative care (PC) is vital in order to assure that the physical, psychological, spiritual, and social needs of patients and their families are addressed before, during, and after treatment for a serious illness. According to the World Health Organization, PC is patient-and family-centered care that optimizes quality of life by anticipating, preventing, and treating suffering. It is holistic care that addresses the physical, psychosocial, and spiritual needs of patients and their families.Methods: To improve early PC in the oncology setting, a free educational series was established for advanced practice providers (APPs). Evaluations were obtained and a post-survey was completed.Results: Evaluation results were positive; staff liked the case presentations and the topics covered. A post-survey was completed. Results demonstrated that most APPs were familiar with basic concepts of symptom management as well as the holistic needs of patients and their families. One area that did not improve was the concept that PC is compatible with aggressive treatment.Conclusions: A PC lecture series for APPs was well received by participants. Participants were able to demonstrate knowledge regarding delivery of PC but failed to understand that PC can be delivered simultaneously with aggressive therapy.Recommendations: Education regarding PC through the disease process and appropriate referrals to PC specialty need to be reinforced. Educating APPs in early PC is beneficial, and creative methods of teaching need to be further explored.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0